Drug Profile
Research programme: antisense RNA inhibitors - Lundbeck/Roche
Alternative Names: RNA antagonists - Lundbeck/RocheLatest Information Update: 16 Jul 2016
Price :
$50
*
At a glance
- Originator Santaris Pharma
- Developer Lundbeck A/S; Roche
- Class Antisense oligonucleotides
- Mechanism of Action Antisense RNA inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- No development reported Neurological disorders
Most Recent Events
- 16 Jul 2016 No recent reports of development identified for research development in Neurological-disorders in Denmark (Parenteral)
- 16 May 2008 Santaris Pharma receives grant from the Danish National Advanced Technology Foundation for development of RNA antagonists in Neurological disorders
- 16 May 2008 Early research in Neurological disorders in Denmark (parenteral)